Cell Therapy News

The FDA cleared an investigational new drug application for PBCAR19B, a chimeric antigen receptor T-cell therapy for patients with relapsed or refractory non-Hodgkin lymphoma, according to the agent’s manufacturer.

CAR T-cell therapy can serve as a frontline treatment option for patients with high risk B-cell lymphomas with CD-19 CAR T-cells, according to a presentation from ASH Annual Meeting and Exposition.

Christian Hinrichs, MD, has been appointed chief of the section of cancer immunotherapy at Rutgers Cancer Institute of New Jersey.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed her thoughts on influential topics to appear at the next the ASH Annual Meeting and Exposition.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed data comparing cytokine release syndrome in CAR T-therapy to COVID-19 at the ASH Annual Meeting and Exposition.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed exciting CAR-T presentations featured at the ASH Annual Meeting and Exposition, including new targets for lymphoid malignancies and CAR modifications to improve safety.

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according to the agent’s manufacturer.

Adoptive cell therapies have proved highly effective for patients with certain advanced cancers, particularly melanoma and hematologic malignancies.

The value of chimeric antigen receptor T-cell therapy for patients with heavily pretreated multiple myeloma can be significant, regardless of whether it leads to a complete and lasting remission.

The Leukemia & Lymphoma has collaborated with cancer institutions, foundations and philanthropic individuals to fund several cancer research projects.